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Abstract 
Background: An effective malaria vaccine is an urgently needed tool to fight against human malaria, the most 
deadly parasitic disease of humans. One promising candidate is the merozoite surface protein-3 (MSP-3) of Plasmo-
dium falciparum. This antigenic protein, encoded by the merozoite surface protein (msp-3) gene, is polymorphic and 
classified according to size into the two allelic types of K1 and 3D7. A recent study revealed that both the K1 and 3D7 
alleles co-circulated within P. falciparum populations in Thailand, but the extent of the sequence diversity and varia-
tion within each allelic type remains largely unknown.
Methods: The msp-3 gene was sequenced from 59 P. falciparum samples collected from five endemic areas (Mae 
Hong Son, Kanchanaburi, Ranong, Trat and Ubon Ratchathani) in Thailand and analysed for nucleotide sequence 
diversity, haplotype diversity and deduced amino acid sequence diversity. The gene was also subject to population 
genetic analysis (Fst) and neutrality tests (Tajima’s D, Fu and Li D* and Fu and Li’ F* tests) to determine any signature of 
selection.
Results: The sequence analyses revealed eight unique DNA haplotypes and seven amino acid sequence variants, 
with a haplotype and nucleotide diversity of 0.828 and 0.049, respectively. Neutrality tests indicated that the polymor-
phism detected in the alanine heptad repeat region of MSP-3 was maintained by positive diversifying selection, sug-
gesting its role as a potential target of protective immune responses and supporting its role as a vaccine candidate. 
Comparison of MSP-3 variants among parasite populations in Thailand, India and Nigeria also inferred a close genetic 
relationship between P. falciparum populations in Asia.
Conclusion: This study revealed the extent of the msp-3 gene diversity in P. falciparum in Thailand, providing the 
fundamental basis for the better design of future blood stage malaria vaccines against P. falciparum.
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Background
Vaccines against human-infecting Plasmodium species 
are considered an indispensible tool for malaria control 
and eradication. To date, RTS/S is the most advanced 
malaria vaccine against the human malaria parasite 
Plasmodium falciparum, the most deadly of the human 
malaria parasites. The RTS/S vaccine is made from the 
circumsporozoite protein (CSP), the essential antigen 
of the sporozoite, and induces immunity against the 
pre-erythrocytic stage of the malaria parasite. Although 
the vaccine has completed the pivotal Phase III clinical 
testing, and subsequently received a positive scientific 
recommendation from European Medical Agency for 
immunization of children against malaria in 2015, the 
efficacy of vaccine against clinical malaria was less than 
50 % in children and infants [1].
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An alternative approach for malaria intervention is to 
develop vaccines against the pathogenic erythrocytic 
stages, aiming to reduce their ability to induce morbidity 
and mortality. The erythrocyte invasion is a critical point 
in the life cycle of malaria, and at this point the mero-
zoites can be targeted by antibodies and subsequently 
eliminated by white blood cells. This type of vaccine 
generally incorporates antigenic proteins that are highly 
expressed on, or associated with, the surface of merozo-
ites, such as the merozoite surface proteins (MSPs). All 
current erythrocytic stage vaccines are now being tested 
in clinical Phase I and II trails, yet in many cases the vac-
cines have had low, or no, impact against clinical malaria 
[2]. One of the key difficulties for malaria vaccine devel-
opment is the structural diversity of the malaria antigens 
that is caused by the extensive genetic polymorphism of 
the antigen-encoding genes. This is attributed to high 
mutation and genetic recombination rates, features com-
monly observed in areas of high malaria endemicity. 
The analyses of P. falciparum diversity in natural infec-
tions by high-throughput sequencing, microarrays and 
genome-wide microsatellite markers revealed that the P. 
falciparum genome is highly diverse [3–5]. A complete 
understanding of the malaria parasite’s biology and the 
extent of genetic diversity in natural parasite popula-
tions will be necessary for improving vaccine design and 
efficacy.
This study will focus on MSP-3, a promising candidate 
antigen for the development of a blood-stage malaria 
vaccine. The MSP-3 protein has a crucial role not only in 
binding to the host red blood cell, but also in protecting 
the parasite against haem that is released during parasite 
egression [6]. The MSP-3 protein is synthesized as 62 kDa 
precursor at the schizont stage and is secreted into the 
parasitophorous vacuole (PV), where it undergoes cleav-
age at its N-terminal sequence to form the mature pro-
cessed form, with a final size of 44–48 kDa [7, 8]. Despite 
a lack of a transmembrane domain or Glycosylphosphati-
dylinisotol (GPI)-anchor containing sequence, the pro-
tein is presumed to attach to the surface membrane as 
a result of protein–protein interactions. The N-terminal 
region of MSP-3 is defined by three blocks of four ala-
nine heptad repeats (AHRs), with the conserved motif 
‘AXXAXXX’, which are separated by short stretches of 
non-repetitive sequences [9]. The alanine residues in 
the AHRs are thought to stabilize the α-helical second-
ary structure [10]. The C-terminal region of MSP-3 com-
prises a glutamic acid-rich region and a putative leucine 
zipper sequence, which are important for trafficking of 
MSP-3 and its binding partners to the PV [11].
Importantly, evidence that the P. falciparum MSP-3 
protein is a target of natural acquired immunity is 
accumulating. First, hyperimmune sera that inhibited 
P. falciparum growth in  vitro in the presence of blood 
monocytes in an antibody-dependent cellular assay 
were shown to contain antibodies targeting MSP-3 [12, 
13]. Subsequently, MSP-3-specific human antibodies 
were shown to suppress P. falciparum growth in immu-
nocompromised mice infected with P. falciparum [14]. 
Immunization with the full-length sequence of P. falcipa-
rum MSP-3 also induced a protective immune response 
and protected Aotus monkeys from subsequent chal-
lenge infection with P. falciparum expressing a homolo-
gous MSP-3 sequence [15]. Antibodies targeting MSP-3 
are also associated with long-term protection against 
clinical malaria [16]. Vaccines have been now designed 
using either MSP-3 alone or in combination with other 
blood-stage antigens, such as the glutamate rich protein 
(GLURP) or MSP-1. For example, the MSP-3/LPS vaccine 
is a long synthetic peptide, consisting of the C-terminal 
portion (corresponding to amino acid positions 154–249) 
of P. falciparum strain FC27, which has been tested in 
Phase I clinical trials [17, 18]. The vaccine was shown to 
be safe, immunogenic and capable of inducing cytophilic 
antibodies that could inhibit P. falciparum erythrocytic 
growth in a monocyte-dependent manner, under both 
in vitro and in vivo conditions [19–21]. The GMZ2 vac-
cine, which consists of a hybrid protein between the 
C-terminal MSP-3 fragment (corresponding to amino 
acid positions 212–318 of P. falciparum 3D7 strain) 
and the N-terminal region of GLURP, has recently been 
developed and evaluated during Phase I trials [22–24]. 
Like the MSP-3 LPS vaccine, GMZ2 was immunogenic 
and well tolerated, and elicited high titres of functional 
antibodies with the capacity to control P. falciparum 
multiplication [25]. Additionally, several studies showed 
that the N-terminal sequences were immunologically 
important and could potentially be considered as a sub-
unit of a malaria vaccine [26, 27]. Altogether, these stud-
ies support that the N and C-terminal regions of MSP-3 
are targets of protective responses and so are considered 
promising malaria vaccine candidates.
The P. falciparum MSP-3 protein is encoded by a sin-
gle locus (PF10_0345; msp-3) that spans 1.1 kb on chro-
mosome 10 [28]. Orthologs of the P. falciparum msp-3 
gene were identified in malaria parasites of African apes 
Plasmodium reichenowi and Plasmodium gaboni [29, 
30], not in the human malaria parasite Plasmodium 
vivax and Asian primate malarias [31]. Comparison of 
msp-3 sequences from laboratory strains of P. falcipa-
rum revealed a dimorphic pattern, with allelic sequences 
falling into the two major classes of 3D7 and K1 (named 
after the P. falciparum strains) [32]. Variation between 
the two classes of msp-3 is largely due to insertion/
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deletion (indel) and nucleotide substitutions within and 
flanking the AHR domains, which define the N-terminal 
domain. Conversely, the C-terminal domain is almost 
entirely conserved [9, 32]. The two allelic types (3D7 
and K1) of the msp-3 gene could be genotyped by aga-
rose gel electrophoresis based size estimation of the poly-
merase chain reaction (PCR) amplification of the msp-3 
gene. Allelic diversity of the P. falciparum msp-3 gene 
was also studied in natural parasite populations, provid-
ing a snapshot of genetic diversity in diverse geographical 
populations [33–35]. Alternatively, the genomes of P. fal-
ciparum natural isolates have been sequenced, providing 
the systematic view of polymorphic sites at msp-3 locus, 
but the variation within allelic type of msp-3 has been 
rarely analysed [3, 4, 36]. Although one study described 
the sequence variation of the msp-3 gene in wild isolates 
of P. falciparum in Thailand and Nigeria [37], the msp-3 
sequence data from Thailand was obtained from a sin-
gle population in Tak at the Thailand–Myanmar border, 
and, to date, there is no report of sequence variation with 
allelic type of msp-3 in other regions of Thailand or other 
countries in Southeast Asia.
To address this question, the msp-3 sequences from 
natural Thai isolates from five known malaria hotspots, 
near the borders between Thailand and three neigh-
bouring countries (Cambodia, Myanmar, Laos) were 
examined. These data provide an overview of the msp-3 
variants and population structure of P. falciparum across 
regions of Thailand, and aid in identifying regions under 
positive selection. This should provide the basis for a bet-
ter design of MSP-3-based malaria vaccines.
Methods
Origins of Plasmodium falciparum
A total of 59 natural isolates of P. falciparum used in the 
present study were the laboratory lines maintained at 
Malaria Laboratory, Department of Biology, Faculty of 
Science, Chulalongkorn University, Thailand. The para-
sites were originally isolated from patients in the five 
endemic areas of Mae Hong Son, Kanchanaburi and 
Ranong at the Thailand–Myanmar border, Ubon Rat-
chathani at the Thailand–Laos border, and Trat at the 
Thailand–Cambodia border between 2002 and 2010 [38]. 
The procedures of parasite collection and in vitro cultiva-
tion were performed as previously described [39]. Micro-
scopic examinations of Giemsa-stained thin blood smears 
were performed to identify the Plasmodium species. The 
parasites were previously genotyped with microsatellites 
and shown to be genetically distinct clones [39], and with 
primers specific to the msp-3 gene [28]. Those P. falcipa-
rum isolates shown to have a single allele of msp-3 were 
chosen for this study.
Genomic DNA preparation, nested PCR and DNA 
sequencing
Genomic DNA was prepared from infected human blood 
using a standard phenol/chloroform extraction method 
[38]. In brief, the blood stage parasites of P. falciparum, 
with 10–20  % parasitaemia were harvested and incu-
bated with 0.05  % (w/v) saponin solution in phosphate 
buffered saline (PBS, pH 7.4). The parasites were lysed 
in buffer (40  mM Tris–HCl, 80  mM EDTA, 2  % (w/v) 
sodium dodecyl sulfate (pH 8.0), supplied with 2 mg/mL 
proteinase K) at 42  °C overnight. The lysate was mixed 
with Tris–HCl saturated phenol (pH 8.0) to precipitate 
proteins and, after phase separation by centrifugation, 
the aqueous phase was harvested. The lysate was then 
mixed with phenol/chloroform/isoamyl alcohol (25:24:1 
(v/v/v), pH 8.0), phase separated as above and the aque-
ous phase harvested. The DNA was precipitated by addi-
tion of a 0.1× volume of 0.3 M sodium acetate (pH 5.2) 
and a 1× volume of absolute ethanol and centrifugation. 
The genomic DNA pellets were washed with 70 % (v/v) 
ethanol and dissolved in TE buffer (10  mM Tris–HCl, 
0.1 mM Na2EDTA, pH 8.0) and stored at −20 °C.
The msp-3 gene was amplified by two-stage nested 
PCR as follows. The first PCR reaction was performed in 
a total volume of 50  µl, containing 200-300  ng of DNA 
template, 2  mM of MgCl2, 200  µM of dNTPs, 0.5  µM 
of each primer (M3F/O and M3R/O) and 2 units (U) of 
FastStart Taq DNA polymerase enzyme in 1X Taq PCR 
buffer (Roche Diagnostics, Germany). Thermal cycling 
was performed with an optimized profile of 95  °C for 
5 min, followed by 40 cycles of 95 °C for 40 s, 56 °C for 
40 s and 68 °C for 80 s, and then a final 68 °C for 10 min. 
The PCR products were diluted 100- or 500-fold in dis-
tilled water and used as the DNA template for the second 
PCR reaction. The second PCR reaction was performed 
in a total volume of 150  µl of the same composition as 
above except for the template and the M3R/I primer 
was used in place of M3R/0. Thermal cycling was per-
formed with an optimized profile of 95  °C for 5  min, 
followed by 30 cycles of 95  °C for 45  s, 57  °C for 45  s 
and 68 °C for 80 s, and then a final 68 °C for 7 min. The 
primer sequences (M3F/O 5′-ATGAAAAGTTTTAT 
AAATATTACTCTTTC-3′, M3R/O 5′-CATGTTAT-
GAATATAAATTATGTTCA-3 and M3R/I 5′-AAT-
GATTTTTAAAATATTTGGATAATTC-3′) correspond 
to nucleotide positions 1,404,192–1,404,220 (the start 
codon at position 1,404,192–1,404,194), 1,405,293–
1,405,268 (the stop codon at position 1,405,254–
1,405,256) and 1,405,254–1,405,227, of the chromosome 
10 of P. falciparum strain 3D7 (NCBI accession number: 
AE014185.2) [30]. The PCR products were analysed by 
agarose gel electrophoresis. Sequencing reactions were 
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performed using BigDye Terminator v1.1 kit (Applied 
Biosystems) with an ABI3730 DNA analyser. DNA 
sequences were manually edited using BioEdit 7.0.0 soft-
ware and aligned using the multiple sequence alignment 
program Clustal Omega [40].
Phylogenetic analysis
Alignment of nucleotide sequences of msp-3 gene was 
performed using BioEdit 7.0.0 software. Segments for 
which a reliable alignment could not be inferred were 
eliminated. Phylogenetic tree searching was implemented 
using the maximum likelihood (ML) method in MEGA 
V6.0. The Bayesian information criterion (BIC), as imple-
mented in MEGA V6.0, was used to identify the best-
fit model of sequence evolution for the trees estimated 
using ML. The evolutionary history was inferred using 
the ML method based on the general time reversible 
with the Hasegawa-Kishino-Yano with gamma distribu-
tion shape parameter (HKY + G) model. The robustness 
of ML trees was evaluated by bootstrap analysis of 1000 
replicates. The msp-3 gene sequence of the chimpanzee 
malaria parasite Plasmodium reichenowi (NCBI acces-
sion number: HG810771 [41]) was used as an out group.
Sequence analysis and statistical analysis
Several measures of genetic polymorphism and neu-
trality tests were calculated using the MEGA software 
[42], including the number of polymorphic sites (S), 
nucleotide diversity (π) as the average number of nucle-
otide substitutions per site between any two sequences, 
the number of haplotypes (H), and haplotype diversity 
(Hd). The nucleotide diversity was also plotted using a 
sliding window with a window length of 60 bases and 
step size of 3  bp, in the DnaSP 5.0 software [43] to 
identify the region(s) of msp-3 that accumulate poly-
morphisms. The mean number of synonymous muta-
tions per synonymous site (dS) and non-synonymous 
substitutions per non-synonymous site (dN) within 
each isolate were calculated using the Nei and Gojob-
ori method [44], with the Jukes and Cantor correction, 
and the statistical differences between dN and dS were 
tested with the Z test of selection (P  <  0.05). A dN/dS 
ratio of greater than 1 at the 95  % confidence interval 
was taken as evidence of positive diversifying selection. 
In addition, three population genetic tests of neutrality 
(Tajima’s D, Fu and Li’D* and Fu and Li’F* tests) were 
applied to the msp-3 sequences to determine whether 
polymorphism takes place at higher or lower frequen-
cies than expected under a neutral model [45, 46]. In 
addition, sliding window plots, with a window length 
of 60 bases and a step size of 3 bp, were generated for 
the analysis of the three neutrality tests above to iden-
tify regions of msp-3 where a significant departure 
from neutrality was observed (P  <  0.05). Differences 
in the distribution patterns (ratios) of MSP-3 variants 
between different geographic populations of P. falcipa-
rum were tested using Wright’s fixation index (Fst) in 
the Arlequin suite version 3.5 software [47], accepting 
significance at the P < 0.05 level.
Results
Nucleotide sequence analysis of the msp‑3 gene 
of Plasmodium falciparum in Thailand
Fragments of the P. falciparum msp-3 gene were success-
fully amplified from 59 human blood samples collected 
from five endemic areas. Thirty-seven samples were 
obtained from three localities at the Thailand–Myanmar 
border, as 12, 13 and 12 isolates from Mae Hong Son, 
Kanchanaburi and Ranong, respectively. In addition, 12 
and ten samples were obtained from Ubon Ratchatani 
and Trat, which were situated at the Thailand–Laos bor-
der and the Thailand–Cambodia border, respectively. The 
derived PCR products were analysed by standard agarose 
gel electrophoresis, as described in Methods, revealing 
that 17 and 42 samples had the 3D7 and K1 allelic types 
of msp-3 (Additional file 1), respectively, giving frequen-
cies of the 3D7 and K1 allelic types of 28.8 and 71.2  %, 
respectively.
A total of 59 partial sequences of msp-3, correspond-
ing to nucleotide positions 232–783  bp (numbered 
from the P. falciparum reference strain 3D7 sequence) 
were generated and used in subsequent analyses. The 
sequence data contain the three blocks of the AHR 
region and the glutamic-rich region. A total of 60 poly-
morphic nucleotide sites (excluding gaps) and two indels 
were observed among the 59 sequences, with an aver-
age pairwise nucleotide diversity (π) of 0.049. Of these 
polymorphic sites, 53 were dimorphic and seven were 
trimorphic (Fig.  1). A sliding method plot with a win-
dow length of 60  bp and a step size of 3  bp revealed a 
π diversity range from 0.0001–0.1797. Significant values, 
which indicate the region of msp-3 accumulating poly-
morphism, were observed between nucleotide positions 
252–552 (Fig. 2a).
Nucleotide sequence alignment also revealed 8 distin-
guishable haplotypes (H1–5, H6A, H6B and H7; Fig.  1) 
with an estimated haplotype diversity (Hd) of 0.828. The 
ML-based phylogenetic analysis of these eight haplo-
types is illustrated in Fig.  3. The 17 sequences with the 
3D7 allele were represented by two haplotypes (H1 and 
H2), while the 42 sequences with the K1 allele were com-
posed of six haplotypes. The H1 and H7 haplotypes had 
the nucleotide sequences of the reference strains 3D7 
and K1, and were the most abundant haplotypes of msp-
3 in Thailand, with an overall frequency of 25 and 34 %, 
respectively, (Additional file 1).
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Fig. 1 Partial nucleotide sequences of the msp-3 gene of Plasmodium falciparum populations in Thailand. Only the nucleotide sequences encoding 
the AHRs of MSP-3, corresponding to nucleotide positions 232–570 after P. falciparum strain 3D7, are shown. H1 and H2 are derived from the 3D7 
allele of msp-3, while the remaining 6 haplotypes (H3–5, H6A, H6B and H7) belong to the K1 allelic type. Two haplotypes, H6A and H6B, encode 
identical amino acid sequences (see Fig. 4). Grey and green labels indicate dimorphic and trimorphic nucleotides, respectively. Asterisks indicate 
dimorphic SNP defining the 3D7 and K1 alleles
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Dimorphism of the 3D7 and K1 alleles of msp-3 was 
attributed to variation in size of the AHR region, being 
339 bp in the 3D7 allele and varying at 366 or 369 bp in 
the K1 allele. A 30-bp insertion fragment, correspond-
ing to nucleotide positions 457–486 of the K1 strain, 
appeared in H3, H4 and H7, whereas a slightly shorter 
27-bp insertion fragment, corresponding to nucleo-
tide positions 457–483, was found in H5, H6A and 
H6B (Fig.  1). In addition to the above indels, 13 single 
nucleotide polymorphism (SNP) loci that were dimor-
phic but conserved within each allelic type were iden-
tified. Of these sites, four codons [234 (GCT/GCA), 
246 (TCC/TCT), 366 (GCA/GCT) and 444 (AAA/
AAG)] resulted in synonymous mutations at positions 
76 (A), 82 (S), 122 (A) and 148 (K), while eight codons 
[247 (GAA/CAA), 270 (AAT/AAA/GAA), 435 (AAA/
ACT/AGT), 436 (TCT/GCT), 440 (TCA/TTA), 445 
and 447 (GCT/ACA), 448 (GAT/AGT/AAT) and 451 
(AGT/GAG/GCT/GAA)] caused non-synonymous 
amino acid substitutions at positions 83 (E/Q), 90 
(N/K/E), 145 (K/T/S), 146 (S/A), 147 (S/L), 149 (A/T), 
150 (D/S/N), and 151 (S/E/A/E), respectively, (Fig.  1). 
The 212-bp sequence towards the C-terminal region of 
MSP-3, corresponding to nucleotide positions 571 and 
783, were monomorphic in all isolates.
Furthermore, when the 17 nucleotide sequences with 
the 3D7 allele (H1 and H2) of msp-3 were analysed sep-
arately, only one SNP locus, at nucleotide position 307 
(GCT/TCT), was detected between the two haplotypes. 
This point mutation resulted in a non-synonymous 
amino acid change at amino acid position 103 (A/S), 
demonstrating the relatively low genetic diversity of 
msp-3 among 3D7 alleles. In contrast, a separate analysis 
of the 42 sequences with the K1 allele (H3, H4, H5, 6A, 
H6B, H7) revealed 51 SNP loci (excluding gaps), resulting 
in 40 non-synonymous mutations and seven synonymous 
mutations. This result, therefore, clearly depicts the dif-
ferent levels of genetic diversity between the K1 and 3D7 
msp-3 alleles.
Because of the observed high level of polymorphism, 
a next goal was to determine whether natural selection 
contributes to the diversity of this gene. The dN/dS ratio 
was calculated using the sequences of the 59 samples as 
described in Methods. When the nucleotide sequences 
encoding the AHR region (nucleotide positions 232–
570) of MSP-3 were analysed, the dN/dS ratio was 1.08 
Fig. 2 Sliding window plots of the average pair-wise nucleotide diversity (π), Tajima’s D values, Fu and Li’s D* values and Fu and Li’s F* values of the 
msp-3 gene of Plasmodium falciparum in Thailand. a The nucleotide diversity was plotted by a sliding window with a window size of 60 bp. and a 
step size of 3 bp. The maximum diversity (π > 0.02) was detected between nucleotide positions 252–552 bp. Sliding window plots of b Tajima’s D 
values, c Fu and Li’s D* values and d Fu and Li’s F* values were performed with a window size of 60 bp. and a step size of 3 bp. Elevated D and F* val-
ues were detected between nucleotide positions 252–552 bp. and 252–561 bp., respectively. Significant D values were located between nucleotide 
positions 252–528, excluding the nucleotide positions 351–375 bp. Red and dash lines indicate P values of <0.05 and <0.02
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Fig. 3 Maximum likelihood tree of Thai Plasmodium falciparum populations based on msp-3 gene analysis. The tree was constructed by the MEGA 
program using msp-3 nucleotide sequences (nucleotide positions 232–783 after P. falciparum 3D7 strain). The sequences are identified with their 
names of parasite isolates. The letters indicate the origin of isolates: MH, Mae Hong Son; K, Kanchanaburi; RN, Ranong; TD, Trat; UB, Ubon Ratchatani. 
The tree was rooted using the sequence of the P. reichenowi msp-3 gene as an out group [41]. Bootstrap values of >50 % are shown. The scale bar 
indicates nucleotide substitutions per site
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(greater than 1) (P = 0.818), although the value did not 
show a significant positive departure from zero. Thus, 
there was a tendency for positive diversifying selec-
tion. Furthermore, the three within-population tests 
for neutrality (Tajima’s D, Fu and Li’s D* and F* tests) 
were all significant, with values of 2.611 (P < 0.01), 1.998 
(P  <  0.02) and 2.644 (P  <  0.02), respectively. To deter-
mine whether specific region(s) of the AHR region was 
under selection, a sliding window plot analysis was per-
formed. The values of D, D* and F* were calculated on 
a window of 60  bp moving in steps of three sites. As 
shown in Fig. 2, the polymorphisms between the nucleo-
tide positions 252–528, excluding monomorphic nucleo-
tide positions 351–375, showed significant departure 
from neutrality in all three tests. For comparison, slid-
ing window plots of nucleotide diversity (π), Tajima’s D 
test, Fu and Li’s D* test and Fu and Li’s F* test a window 
size of 100 bases and a step size of 25 bases (default set-
ting) were also analysed [48]. Regions of msp-3 with 
significant values from the sliding window plots with 
a window size of 100 bases and a step size of 25 bases 
and a window size of 60 bases and a step size of 3 bases 
were largely overlapped (see Additional file 2). The alter-
nation of a window size and a step size of sliding win-
dow plots did not affect the conclusion. Altogether, the 
comparison of the non-synonymous and synonymous 
mutations, D, D* and F* all suggested that the polymor-
phisms in the AHR region of MSP-3 were maintained by 
positive diversifying selection, which was in agreement 
with the previous neutrality test analysis using the msp-3 
sequences from Thailand and Nigeria [37].
Amino acid sequence analysis
The deduced amino acid sequences of P. falciparum 
MSP-3 were translated from the DNA sequences of the 
eight haplotypes of the 59 nucleotide sequences. The 
translated sequences represent the three blocks of the 
AHR regions, covering amino acid positions 78–190 of 
the reference strain 3D7. Each DNA haplotype of msp-
3 produced a unique amino acid sequence, except for 
haplotypes 6A and 6B that generated the same amino 
acid sequences and so seven amino acid sequence vari-
ants were found (Table  1). There were two amino acid 
sequence variants (variants 1 and 2) for two haplotypes 
of the 3D7 allele, and five amino acid sequence vari-
ants (variants 3–7) for six haplotypes of the K1 allele 
(Fig. 4a).
The amino sequence analysis showed a total of 45 
amino acid changes across the 59 sequences. Of these 
polymorphic sites, 37 were dimorphic and eight were tri-
morphic. In order to determine the distribution of amino 
acid polymorphisms across the AHR region of the MSP-3 
sequence, the location of substitutions and the number 
of amino acid types observed at each site were plotted. 
As shown in Fig. 4b, the amino acid polymorphisms were 
predominantly clustered between amino acid positions 
80 and 169, located between block 1 and the first heptad 
repeat of block 3. Block 1 of the AHR region also con-
tained the highest number of polymorphic sites, four of 
which were trimorphic amino acid substitutions. The 
other trimorphic sites were clustered at the non-repeti-
tive sequence between blocks 2 and 3.
Despite this diversity, block 1 in the seven MSP-3 vari-
ants also contained a fifth AHR based on the ‘AXXAXXX’ 
motif except with leucine (L), rather than alanine (A) in 
the d position (Fig. 4a), similar to other reports [32, 49]. 
In addition, blocks 2 and 3 of the AHR region in the 
seven variants contained four AHRs except for block 2 
of variants 1, 2 and 7, and block 3 of variants 5, 6 and 7, 
which contained only three AHRs.
Distribution of MSP‑3 variants in Plasmodium falciparum 
in Thailand
The overall prevalence and distribution patterns of the 
seven MSP-3 variants in P. falciparum populations in Thai-
land are shown in Fig.  5. The two most prevalent types, 
variants 1 and 7, co-existed in all sampled sites, although 
the proportions of these variants varied remarkably in 
the different geographical locations of the parasites. Vari-
ant 1 was the most prevalent MSP-3 type in the Ubon 
Ratchatani population, at a frequency of 66  %, whereas 
variant 7 was the most prevalent type in the Ranong and 
Kanchanaburi populations, at a frequency of 59 and 38 %, 
respectively. Interestingly, in the P. falciparum populations 
in Mae Hong Son and Trat, variant 3 appeared to be more 
prevalent than variants 7 and 1, with a frequency of 42 and 
40  %, respectively. The other variants (2–5 and 6) were, 
however, minor variants, each of which was represented at 
less than 10 % in each population.
In addition, Fig.  5 also summarizes the different lev-
els of genetic diversity in the P. falciparum populations 
based on the MSP-3 variants. Those in Mae Hong Son, 
Kanchanaburi, Ranong, and Trat had five different vari-
ants. In contrast, only three variants were present in the 
Ubon Ratchatani population suggesting that the genetic 
diversity of P. falciparum in the Thai–Laos border was 
lower than in the Thai–Myanmar and Thai–Cambodia 
borders.
In order to compare patterns of distribution of MSP-3 
variants between P. falciparum populations in Thailand, 
pair-wise inter-population comparison were conducted 
for each population using Wright’s Fixation index (Fst). 
The Fst values were significant (P < 0.05) between Ubon 
Ratchatani and the Trat, Ranong and Mae Hong Son 
populations, but not between those at Ubon Ratchatani 
and Kanchanaburi (Table  1). This indicates potential 
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population sub-division between P. falciparum popula-
tions in Ubon Ratchatani and the other regions in Thai-
land, excluding Kanchanaburi due to their sharing of the 
same three variants (1, 4 and 7) (Fig. 4). The distribution 
of MSP-3 patterns between the four populations in Mae 
Hong Son, Kanchanaburi, Ranong, and Trat showed low 
and non-significant Fst values, indicating a similar distri-
bution of the MSP-3 variants between these four P. falci-
parum populations.
Comparison of MSP‑3 variants in the Plasmodium 
falciparum reference strains and natural isolates
The nucleotide sequences of the msp-3 gene from 14 lab-
oratory clones from the P. falciparum genome database 
were retrieved from the National Center for Biotechnol-
ogy Information (NCBI) website (see Additional file  3). 
The analysis showed that seven of these strains (HB3 
from Honduras, RO-33 from Ghana, 7G8 from Bra-
zil, Santa Lucina from El Salvador, RAJ116 from India, 
MaliPS096_E11 from Mali, NF54 of unknown origin) 
had variant 1 of MSP-3, similar to that of P. falciparum 
strain 3D7. The other seven strains (2,000,708 from Tan-
zania, NF135/5.C10 from Cambodia, VS/1 and Vietnam 
Oak-Knoll from Vietnam, Dd2 from Laos, IGH-CR4 
from India, FCH/4 from Philippines) carried variants 3, 
4, 6 and 7 of MSP-3, all of which were derived from the 
K1 allele. The results demonstrate the diversity of MSP-3 
variants in laboratory clones.
In addition, the msp-3 sequences of natural isolates 
of P. falciparum in Thailand, India and Nigeria were 
obtained through the literature search at the NCBI and 
Scopus websites (Additional file 4) [37]. The data showed 
that P. falciparum from Tak province (n  =  50) had the 
same seven MSP-3 sequence variants as in this study 
of Thai populations, and so all these variants were re-
discovered and confirmed in the present study. The Fst 
analysis also showed that the P. falciparum population 
from Tak province was similar to P. falciparum in other 
regions in Thailand, except for Ubon Ratchanani, in 
which the 3D7 allele was the dominant type (Table 1). In 
addition, the P. falciparum population in India (n = 56) 
had five of the seven MSP-3 variants found in Thailand. 
This broadly similar distribution pattern of MSP-3 vari-
ants between P. falciparum populations in South Asia 
and Southeast Asia supports the existence of gene flow 
between these parasite populations or that the parasite 
populations are closely genetically related. In contrast, 
nine variants of MSP-3 were identified in P. falciparum 
populations in Nigeria (n =  51), of which five (variants 
8–12, see Additional file  5) were distributed exclusively 
in the African population, suggesting that P. falciparum 
in Africa were genetically distinct from those in Asia. The 
population differentiation between P. falciparum popu-
lations in Asia and Africa was also supported by the Fst 
analysis (Table 2).
Discussion
The MSP-3 of the human malaria parasite P. falciparum 
is a key surface antigen and is considered a candidate 
antigen for the development of a blood-stage malaria 
vaccine. While the msp-3 gene sequences of labora-
tory strains of P. falciparum are extremely useful for the 
development of current MSP-3 vaccines [17, 22], the 
study of msp-3 sequences in natural parasite populations 
can be applicable for monitoring the vaccine efficacy 
and designing relevant local policies for malaria control. 
A previous, preliminary, cross-sectional survey of the 
msp-3 allelic diversity in natural P. falciparum popula-
tions in Thailand demonstrated the biased distribution of 
the K1 allele in four parasite populations at the Thailand–
Myanmar and Thailand–Cambodia borders, while the 
3D7 allele of msp-3 was more prevalent in a population at 
the Thailand–Laos border [28]. This raises the questions 
as to how and why the population structure of P. falcipa-
rum at the Thailand–Laos border is genetically distinct 
from other regions in Thailand. The present study aimed 
to investigate the sequence diversity of the msp-3 gene in 
P. falciparum populations in Thailand.
The main finding of this work was that eight DNA hap-
lotypes of the msp-3 gene were detected, with two and 
Table 1 Summary of the pairwise Fst values of MSP-3 variants between Plasmodium falciparum populations in Thailand
Data from Tak province is from [37]
Asterisks indicate the significant Fst values (sign of population differentiation)
* P < 0.05
** P < 0.01
Location Trat Kanchanaburi Mae Hong Son Ubon Ratchathani Ranong
Kanchanaburi 0.04492 (P = 0.17)
Mae Hong Son 0.0645 (P = 0.92) 0.04634 (P = 0.17)
Ubon Ratchathani 0.18483* (P = 0.02) 0.09703 (P = 0.08) 0.26705** (P = 0.00)
Ranong 0.08137 (P = 0.09) 0.02499 (P = 0.26) 0.05051 (P = 0.19) 0.28465** (P = 0.00)
Tak 0.08493 (P = 0.06) 0.0086 (P = 0.30) 0.06375 (P = 0.07) 0.20385** (P = 0.00) 0.03830 (P = 0.92)
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variant 1 AKKASEDAEK AANDAENASK EAEEAAKEAV NLKESDKSYT KAKEACTAAS 127 
variant 2 AKKASEDAEK AANDAENASK EAEEASKEAV NLKESDKSYT KAKEACTAAS 127
variant 3 AKQASQDAEQ AAKDAENASK EAEEAAKEAV NLKESDKSYT KAKEACTAAS 127
variant 4 AKQASQDAEQ AAKDAENASK EAEEAAKEEV NLKESDKSYT KAKEACTAAS 127
variant 5 AKQASQDAEQ AAKDAEQAAK DAEQASKDAE KLKESDESYT KAKEACTAAS 127
variant 6 AKQASQDAEQ AAKDAEQAAK DAEQASQDAE KLKESDESYT KAKEACTAAS 127
variant 7 AKEASQDAEK AAEEAEKAAE QAEQASKDAE KLKESDESYT KAKEACTAAS 127
a  d   a   d   a  d    a  d   a   d             a  d    
variant 1 KAKKAVETAL KAKDDAEKSS KADSI----- -----STKTK EYAEKAKNAY 167 
variant 2 KAKKAVETAL KAKDDAEKSS KADSI----- -----STKTK EYAEKAKNAY 167
variant 3 KAKKAVETAL KAKDDAETAL KTSETPEKPS RINLFSRKTK EYAEKAKNAY 177
variant 4 KAKKAVETAL KAKDDAETAL KTSETPEKPS RINLFSRKTK EYAEKAKNAY 177
variant 5 KAKKAFETAS NAKKAAESAL KTNAD-EKPS RINLFSRKTK EYAEQVEKDY 176
variant 6 KAKKAFETAS NAKKAAESAL KTNAD-EKPS RINLFSRKTK EYAEQVEKDY 176
variant 7 KVKKAFETAS NAKKAAESAL KTNETGERNS RNNFYTTKTK EYAGKVEKDY 177
a  d   a   d   a  d a  d
variant 1 EKAKNAYQKA NQAVLKAKEA SSY 190
variant 2 EKAKNAYQKA NQAVLKAKEA SSY 190
variant 3 EKAKNAYQKA NQAVLKAKEA SSY 200
variant 4 EKAKNAYQKA NQAVLKAKEA SSY 200
variant 5 ERAKNAYQKA NQAVLKAKEA SSY 199
variant 6 ERAKNAYQKA NQAVLKAKEA SSY 199
variant 7 ERAKNAYQKA NQAVLKAKEA SSY 199
a  d   a   d   a  d 
b
a
Fig. 4 Partial amino acid sequences of Plasmodium falciparum MSP-3. a Alignment of the deduced amino acid sequences encoding the AHRs, 
revealing seven sequence variants. Dimorphic and trimorphic amino acid residues are highlighted in grey and green, respectively. Variants 1 and 
7 are identical to the MSP-3 sequences of the P. falciparum reference strains 3D7 and K1, respectively. Two haplotypes (H1 and H2) of the 3D7 
allele encode variants 1 and 2, while the other five haplotypes encode variants 3–7. Note that haplotypes 6A and 6B encode the same amino acid 
sequence (variant 6). b Location of the polymorphic amino acid residues in MSP-3 sequences. The positions of MSP-3 sequences are numbered after 
P. falciparum strain 3D7
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six haplotypes representing the 3D7 and K1 allelic types, 
respectively. Although all the haplotypes had previously 
been detected in P. falciparum samples from the Tak 
province in western Thailand [37], the results from the 
present work confirmed the existence of sequence poly-
morphism in the P. falciparum msp-3 gene across diverse 
P. falciparum populations in Thailand. The alignment of 
the nucleotide sequences of msp-3 also revealed sets of 
dimorphic SNPs and indel mutations, defining the 3D7 
and K1 allelic types, and was supported by the ML-based 
phylogenetic analysis. The majority of the dimorphic 
sites were predominantly clustered in the N-terminal 
extremity within and flanking the AHRs, consistent with 
previous reports [32, 37], and supporting the view that 
the msp-3 polymorphism in laboratory strains and nat-
ural isolates is highly restricted. The sequence analysis 
also showed a lack of genetic recombination between the 
K1 and 3D7 allelic types or alternative polymorphisms in 
natural P. falciparum populations in Thailand, although 
novel alleles of msp-3 were detected in Iran and African 
countries at a very low frequency [33, 35]. The lack of 
recombination between the two allelic types is likely due 
to the high divergence of the dimorphic sequence that 
then prevents crossing over at meiosis. Alternatively, the 
msp-3 sequence dimorphism may be maintained in P. 
falciparum by balancing selection that has prevented the 
loss of divergent alleles over a long period of time [29, 
50].
Fig. 5 Frequency and distribution of MSP-3 variants in Thai populations of Plasmodium falciparum. Plasmodium falciparum samples were col-
lected from endemic regions of Thailand: Mae Hong Son (MH), Kanchanaburi (K), Ranong (R), Trat (T), and Ubon Ratchatani (U). Ubon Ratchathani 
is located at the Laos–Thailand border, Trat is located at the Cambodian–Thailand border, and the other three sites are located along the Myan-
mar–Thailand border. Numbers (n) of the total parasite isolates in Thailand (overall) or the parasites from each locality are displayed in the bracket. 
Numbers in pie charts represent percentage of MSP-3 variants. Variants 1 and 2 are from the 3D7 allele of msp-3, while the others belong to the K1 
allele of msp-3
Table 2 Summary of pairwise Fst values of MSP-3 variants 
between  Plasmodium falciparum populations in Thailand, 
India and Nigeria
** Indicate significant (P < 0.01) Fst values (sign of population differentiation)
a Sequence data from Thailand included the data generated in the present work 
only [37]
b Sequence data from India was retrieved from the NCBI nucleotide database 
(see Additional files for details)
c Sequence data from Nigeria was obtained from Polley et al. [37]
Thailanda India
Indiab 0.00983 (P = 0.17)
Nigeriac 0.10673** (P = 0.00) 0.14867** (P = 0.00)
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The significantly elevated Tajima’s D, Fu and Li’ D*, Fu 
and Li’ F* values indicated that the Thai populations of 
P. falciparum exhibit a significant departure from neutral 
equilibrium expectations for the msp-3 gene. This result 
was consistent with the previous analysis using the msp-3 
sequences from Tak province, Thailand [37]. Sliding win-
dow plot analysis of the neutrality tests also showed the 
AHRs of msp-3 accumulated a significantly higher rate of 
mutations and such polymorphism was likely to be main-
tained by frequency-dependent selection, presumably 
caused by protective immunity. This is in agreement with 
previous immunological data that the N-terminal region 
of MSP-3 contains epitopes that induce allelic-specific 
protective antibodies, or represent the sites of antigenic 
diversity among MSP-3 polypeptides [13, 26, 51, 52]. It is 
also interesting to note that despite the diversity within 
the N-terminal domains, the copy number and repeats of 
the ‘AXXAXXX’ motif is highly conserved. This reflects 
the necessity to maintain the residue contact that is criti-
cal for the α-helical secondary structure formation [9].
In contrast to the polymorphic N-terminal region, 
the C-terminal region of MSP-3 is relatively conserved 
among the various P. falciparum isolates in Thailand. The 
most probable explanation for the limited diversity at the 
AHR franking region is the functional constraint of the 
protein. This part of the protein facilitates the oligomeri-
zation of the proteins, which is essential for the binding 
of haem released from unprocessed haemoglobin dur-
ing parasite egression [6, 53]. Alternatively, this region of 
the protein may play an important role in the invasion of 
the host erythrocyte, as truncation of MSP-3 to remove 
the leucine zipper but to retain the AHR and glutamic-
rich regions led to inference with normal trafficking of 
MSP-3, and the transgenic parasites were less efficient at 
invading host erythrocytes [11].
It has been shown that other malaria parasite antigens 
also exhibited dimorphism, such as MSP-1 and MSP-2 
[54–56]. There have been reports of statistically significant 
differences in the proportions of alleles at the msp-1 and 
msp-2 loci between mild and severe malaria cases [57–61]. 
However, in a genetic analysis of P. falciparum msp-3 in 
Peru correlation between the msp-3 alleles and symptom 
status was not detected [62]. It would be of interest to 
investigate whether the dimorphism in msp-3 locus was 
also associated with severe or mild malaria in Thailand and 
other endemic regions. Possible disease associations may 
need to be tested in further studies by analyzing parasite 
alleles alongside measurements of clinical status of patients 
and allele-specific immune responses in the same subjects.
In addition to the allelic dimorphism, polymorphisms 
were also detected within each of the K1 and 3D7 allelic 
types. A large number of polymorphic sites and indel 
mutations were detected among six haplotypes of the K1 
alleles, while only a dimorphic site was found between 
two haplotypes of the 3D7 alleles. This indicates that the 
levels of genetic diversity within the K1-allelic type are 
much higher than those of the 3D7-allelic sequences, and 
is probably due to the greater prevalence of the K1 allele 
in parasite populations in Thailand. Interestingly, in P. fal-
ciparum population in Peru, the majority of the parasites 
(~90 %) possessed the 3D7 allele [62]. The study showed 
that about 1.8  % of the samples with the 3D7 allele 
(n = 570) had the non-synonymous mutation at nucleo-
tide position 203 (C203T), indicating the low genetic 
diversity in the 3D7 allele of msp-3. These results may 
support the view that the 3D7 allele of msp-3 originates 
from introgression from another Plasmodium species, or 
it recently emerged from the K1 allele, or a recent intro-
duction of 3D7 alleles to the endemic regions [29, 37, 62].
The sequence analysis presented here may be useful in 
predicting target sites in MSP-3 for protective immunity. 
The data presented here suggest that the AHR in the N-ter-
minal region of MSP-3 contains allelic-specific epitopes 
that are immunogenic than the conserved sequences. 
This notion is supported by the clinical immunological 
analysis of anti-MSP-3 antibodies in Gambian children, 
which showed a bias in reactivity towards either the K1 
or 3D7 type recombinant protein [37], suggesting that 
allele-specific epitopes in MSP-3 may induce stronger anti-
body responses than the conserved epitopes. Similarly, in 
cohort studies in Kenya and Peru, antibodies responses to 
allelic specific epitopes of MSP-3 were more common than 
those to a conserved C-terminal region of MSP-3 [13, 51]. 
Interestingly, these studies also revealed that allelic-spe-
cific antibody responses to MSP-3 were associated with a 
lower risk of clinical malaria episodes [13, 37]. However, 
the leucine zipper-like domain at the C-terminus of MSP-3 
was excluded in this analysis and so it is possible that this 
domain was the target of protective immunity. Indeed, it 
has been reported that antibodies to the conserved C-ter-
minal region of MSP-3 were also associated with clinical 
protection [27, 63]. Overall, these studies suggest that the 
N- and C-terminal regions of MSP-3 are targets of host 
protective immunity, and either or both parts of them or 
the full-length MSP-3 may be used as vaccine candidates. 
Combining the effect of allele-specific immunity together 
with that induced to the conserved C-terminal region of 
MSP-3 gene may provide a vaccine of long-term usefulness.
Last but not least, the sequence analysis of the msp-3 
gene could infer the population structure of P. falcipa-
rum in Thailand, where the distribution pattern of MSP-3 
variants depicts a differential genetic diversity among the 
populations in Thailand. In contrast to a previous study, in 
which msp-3 alleles were classified into two types by PCR 
[34], the sequence information of msp-3 showed that there 
were as many as five variants of MSP-3 in all of the parasite 
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populations examined except for that in Ubon Ratchatani. 
This result indicates that the levels of genetic diversity of 
P. falciparum near the Thailand–Myanmar and Thailand–
Cambodia borders were greater than that at the Thailand–
Laos border. The Fst index revealed that the P. falciparum 
population structure in Ubon Ratchatani was similar to 
that at Kanchanaburi, since the two populations shared the 
same three MSP-3 variants. This finding may suggest the 
origin and gene flow between the parasite populations in 
Thailand. The Fst analysis of MSP-3 variants in Thailand, 
India and Nigeria also indicated that P. falciparum popula-
tions in Thailand and India were more closely related than 
those parasites in Nigeria. This finding was also supported 
by the previous genome-wide studies that demonstrated 
population subdivision by continent in P. falciparum natu-
ral populations [4, 64]. The distribution map of the MSP-3 
variants also showed that variants 1 of the 3D7 type and 7 
of the K1 type were the most abundant types. In fact, these 
two variants were also present in P. falciparum popula-
tions in India and Nigeria, despite different geographical 
origins. If the full-length MSP-3 was developed as a vac-
cine, it would be beneficial to include both allelic forms, 
i.e., variants 1 and 7 as the representative allele of the 3D7 
and K1 types in a vaccine formulation. Such a vaccine 
might improve the efficacy against clinical malaria without 
increasing the selection pressure on the locus.
Conclusion
This study extends the understanding of genetic vari-
ation in the MSP-3 protein and prevalence of MSP-3 
alleles in natural populations of P. falciparum in Thailand. 
The nucleotide sequence analysis of msp-3 revealed that 
the polymorphisms that define allelic classes of msp-
3 are attributed to the indel and SNPs in the gene. The 
sequence information also aids in identifying regions 
under positive selection, thereby providing knowledge 
for a better design of any MSP-3-based malaria vaccine, 
as well as revealing the population structure of P. falcipa-
rum across Thailand, which is of use for monitoring and 
control of this parasite.
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